Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Siemens Healthineers Enters Agreement with HORIBA Medical

By LabMedica International staff writers
Posted on 16 Oct 2017
Siemens Healthineers (Erlangen, Germany) and HORIBA Medical (Montpellier, France) have entered into a long-term agreement to bring new and innovative hematology solutions to the market globally.

Siemens Healthineers offers products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. More...
HORIBA Medical designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medical laboratories, clinics and university hospitals.

With HORIBA Medical as the original equipment manufacturer to complement the Siemens Healthineers portfolio, the companies will provide customers with expanded options to fulfill their hematology and multidisciplinary solution needs. Through this alliance, Siemens Healthineers aims to help laboratories transform care delivery by providing complete multidisciplinary solutions for in vitro diagnostics testing.

"With our commercial strength and global installed base of customers combined with HORIBA Medical's innovative technologies, the relationship will expand the hematology solutions available to laboratories for diagnostics testing worldwide," said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers.

“Our long-term vision and continuous investments coupled with our outstanding employees have resulted in innovative hematology technology solutions. I am extremely pleased that this long-term vision has resulted in an alliance with Siemens Healthineers” said Mr. Atsushi Horiba, Chairman, President & CEO of HORIBA, Ltd.

“This alliance provides HORIBA Medical the opportunity to address the multidisciplinary requirements along with complimentary innovative technology of Siemens Healthineers. HORIBA Medical will continue offering innovative technology solutions through its Yumizen 2 brand and current distribution channels.” said Dr. Jai Hakhu, Executive Corporate Officer of HORIBA, Ltd. and President of HORIBA Medical.


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
Specimen Radiography System
TrueView 200 Pro
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.